A safety and efficacy pilot study of protein A immunoadsorption in severe anti-N-methyl-D-aspartate receptor encephalitis

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025104

Enrollment

Unknown

Registered

2019-08-11

Start date

2019-08-10

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anti-N-methyl-D-aspartate receptor encephalitis

Interventions

Case series:immunoadsorption

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years male or female; 2. Patients diagnosed with anti-NMDAR Encephalitis; 3. mRS 4 or 5; 4. Informed consent by family members.

Exclusion criteria

Exclusion criteria: 1. Infectious encephalitis (such as viral encephalitis, suppurative encephalitis, etc.); 2. Patients who are receiving angiotensin converting enzyme inhibitors (ACEI) and cannot discontinue the drug; 3. Comorbidity with infectious disease, moderate to severe chronic renal insufficiency, liver dysfunction, and other organs dysfunction; 4. Presence of other neurological or psychological diseases; 5. Hematological disorders: coagulopathy, PLT<100x10^9/L); 6. Prone to allergies; 7. Severe systemic circulatory failure that is difficult to correct with medication; 8. Pregnant (or possibly pregnant) or lactating women.

Design outcomes

Primary

Measure	Time frame
safety;efficacy;	—

Secondary

Measure	Time frame
hospital stays;Hospitalization expense;clinical manifestation;titer of NMDAR;	—

Countries

China

Contacts

Public ContactBingjun Zhang

the Third Affiliated Hospital of Sun Yat-sen University

124723169@qq.com+86 020-85252327

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026